Introduction {#s1}
============

Restenosis is a complex disease for which the causative mechanisms have not yet been fully identified. Despite medical advances, restenosis still remains a significant complication after percutaneous coronary intervention (PCI).[@pone.0042401-Jukema1] Identification of risk factors and underlying mechanisms could not only be useful in risk stratification of patients, they also contribute to our understanding of this condition. In addition, these factors could provide evidence on which to base individually tailored treatment and aid in the development of novel therapeutic modalities.[@pone.0042401-Jukema2] Unraveling the mechanisms leading to restenosis development remains challenging. Genetic susceptibility is known to play a role in the individuals risk of developing this complication.[@pone.0042401-Jukema1] Many studies have focused on identification of genetic markers associated with restenosis. Over the last decades genetic research has developed from candidate gene approaches [@pone.0042401-Kastrati1]--[@pone.0042401-Monraats1] to multiplex arrays [@pone.0042401-Monraats2] and finally to genome wide association studies (GWAS).[@pone.0042401-Sampietro1] Genetic variation in large array of plausible candidate genes have been associated with restenosis, however, consistent replication of the reported markers is scarce.[@pone.0042401-Jukema1] Possible explanations for this lack of consistency are the small sample size of many (especially relative more dated) studies, phenotype heterogeneity and lack of proper replication cohorts.

Currently more and more GWAS are being performed, investigating many diseases, including cardiovascular diseases.[@pone.0042401-ODonnell1], [@pone.0042401-Keating1] An advantage of GWAS is the hypothesis-free approach of this method, enabling identification of new genetic loci associated with the disease of interest. With respect to restenosis, a disadvantage of the GWAS approach is that due to the complexity of the disease the effect size of individual genetic markers is likely to be small and therefore hard to detect. Moreover, the availability of (large) replication cohorts is very limited. In 2011, the first GWAS on restenosis in the GENetic DEterminants of Restenosis (GENDER) study identified a new susceptibility locus on chromosome 12.[@pone.0042401-Sampietro1] The fact that this GWAS only identified this previously unknown locus does not mean that genetic variation in the previously proposed candidate genes does not affect restenosis development. It merely indicates that the influence of other individual markers is probably too small to detect in the GWAS setting. Especially for the complex traits, a more appropriate approach to interpret GWAS data is to analyze the combined effect of a single nucleotide polymorphism (SNP) set, grouped per pathway or gene region.[@pone.0042401-Ma1] To date, investigation into a possible joined effect of multiple genetic markers for restenosis has not been performed.

The goal of the current study is to investigate whether the last decade of research on genetics of restenosis has led to a set of genes that is associated with restenosis in a set-based analysis using the available genotypic data of the GENDER databank.

Methods {#s2}
=======

Gene Selection {#s2a}
--------------

Candidate genes previously associated with restenosis were selected after a search of literature of papers published up to November 2011. Genes were identified searching MEDLINE using keywords as 'genetic polymorphism', 'candidate gene', 'restenosis' and 'percutaneous coronary intervention'. Selection criteria included a sample size of \>250 patients and the observation of a significant association of a SNP with restenosis. The final set included 36 genes. All available SNPs from the GENDER GWAS databank within a 10-Kb window around these genes were analyzed.

Study Population {#s2b}
----------------

The design of GENDER and the genome-wide association study (GWAS), which has been performed in a subset of this study population, have both been described previously.[@pone.0042401-Sampietro1], [@pone.0042401-Agema1] In brief, GENDER included 3,104 consecutive unrelated symptomatic patients treated successfully by PCI for angina. The study protocol conforms to the Declaration of Helsinki and was approved by the ethics committees of each participating institution. Written informed consent was obtained from each participant before the PCI procedure. During a follow-up period of 9 months, the endpoint clinical restenosis, defined as renewed symptoms requiring target vessel revascularization (TVR) either by repeated PCI or CABG, by death from cardiac causes or myocardial infarction not attributable to another coronary event than the target vessel, was recorded. During follow-up, 346 patients developed clinical restenosis. Blood samples were collected at the index procedure for DNA isolation. The GWAS was performed in 325 cases of restenosis and 630 controls matched by gender, age, and some possible confounding clinical variables for restenosis in the GENDER study such as total occlusion, diabetes, current smoking and residual stenosis. Genotyping was performed using the Illumina Human 610-Quad Beadchips following the manufacturer's instructions. After genotyping, samples and genetic markers were subjected to a stringent quality control protocol. The final dataset consisted of 866 individuals (295 cases, 571 controls) and 556,099 SNPs that passed all quality control criteria, together covering 89% of the common genetic variation in the European population.[@pone.0042401-Sampietro1], [@pone.0042401-Sampietro2] Imputation was performed with MACH software based on the HapMap II release 22 CEU build 36 using the default settings.[@pone.0042401-Li1] This program infers missing genotypes based on the known genotypic data of the samples together with haplotypes from a reference population provided by HapMap taken into account the degree of linkage disequilibrium (LD). After subsequent quality control, we excluded SNPs for further analyses with a call rate lower than 95% (n = 3335) or with a significant deviation from Hardy--Weinberg equilibrium (HWE) in controls (P\<0.00001) (n = 79). The final GENDER Biobank dataset consisted of 866 (295 cases, 571 controls) individuals and 2,571,586 SNPs.

Statistical Analysis {#s2c}
--------------------

The statistical analyses were performed using the set-based test of PLINK v1.07.[@pone.0042401-Purcell1] During this test, first a single SNP analysis of all SNPs within the set is performed. Subsequently a mean SNP statistic is calculated from the single SNP statistics of a maximum amount of independent SNPs below a certain p-value threshold. If SNPs are not independent and the LD (expressed in R^2^) is above a certain threshold, the SNP with the lowest p-value in the single SNP analysis is selected. This analysis is repeated in a certain amount of permutations of the phenotype. An empirical p-value for the SNP set is computed by calculating the number of times the test statistic of the simulated SNP sets exceeds that of the original SNP set. For the analysis of this study, the parameters were set to p-value threshold \<0.05, R^2^ threshold \<0.1, maximum number of SNPs  = 5 and 10,000 permutations.

Initially, the set including all 36 genes is tested as a whole for the association with restenosis. Subsequent analysis of the individual genes will be justified only when the complete set is significantly associated with the endpoint.

Results {#s3}
=======

Patient characteristics are presented in [Table 1](#pone-0042401-t001){ref-type="table"}. No significant differences were found between cases and controls regarding the known risk factors for restenosis (age, diabetes, smoking, stenting and previous restenosis). Hypertension and multivessel disease were more common in the cases compared to the controls.

10.1371/journal.pone.0042401.t001

###### Demographic, clinical and lesion characteristics of the study population.

![](pone.0042401.t001){#pone-0042401-t001-1}

                          Cases (n = 295)   Controls (n = 571)   p-value
  ---------------------- ----------------- -------------------- ---------
  Age (years)                62.8±10.6          62.4±10.9         0.59
  BMI (kg.m^−2^)             26.7±3.6            27.1±3.7         0.20
  Male sex                   213 (72)            421 (74)         0.63
  Diabetes                    58 (20)            119 (21)         0.68
  Hypercholesterolemia       179 (61)            341 (60)         0.79
  Hypertension               138 (47)            211 (37)         0.005
  Current smoker              68 (23)            148 (26)         0.36
  Family history of MI       117 (40)            210 (37)         0.41
  Previous MI                119 (40)            246 (43)         0.44
  Stable angina              188 (64)            400 (68)         0.06
  Multivessel disease        155 (53)            248 (43)         0.01
  Restenotic lesion           23 (8)              48 (8)          0.76
  Total occlusion             57 (19)            97 (17)          0.40
  Type C lesion               95 (38)            154 (27)         0.11
  Stenting                   199 (68)            385 (67)         0.99

Values were given as n (%) or mean ± SD. Patients using anti-diabetic medication or insulin at study entry were considered to be diabetics. Hypertension was defined as a blood pressure of either above 160 mmHg systolic or 90 mmHg diastolic. Hypercholesterolaemia was defined as total cholesterol concentrations of above 5 mmol/L. BMI: body mass index, MI: myocardial infarction. P-values are determined by Pearsons Chi-Square (discrete variables) or unpaired 2-sided t-test (continuous variables).

In [Figure 1](#pone-0042401-g001){ref-type="fig"} the QQ-plot of the GENDER GWAS after imputation is shown, demonstrating that no genomic inflation has occurred in this analysis (lambda  = 1.027). The complete set of 36 genes, previously associated with restenosis in literature, contained 2,581 SNPs. A detailed description of the individual studies and candidate genes can be found in [Table 2](#pone-0042401-t002){ref-type="table"}. The largest gene was chemokine (C-X3-C motif) receptor 1 (CX3CR1) of 316.54 kb, contributing 384 SNPs (14.8%), and glutathione peroxidase 1 (GPX1) was with 1.18 kb the smallest gene, only contributing 8 SNPs (0.3%). Analysis of the complete set using the set-based test demonstrated a significant association with clinical restenosis, with an empirical p-value of 0.024.

![Q-Q plot for the GWAS after imputation on clinical restenosis in the GENDER study population. Lambda  = 1.027.](pone.0042401.g001){#pone-0042401-g001}

10.1371/journal.pone.0042401.t002

###### Candidate genes and the studies that reported their association with restenosis.

![](pone.0042401.t002){#pone-0042401-t002-2}

  [Candidate gene]{.ul}                                               [Literature based study characteristics and results]{.ul}                                                                                                         
  ------------------------------------------------------------------ ----------------------------------------------------------- ---------------- ------ ------ ------- --------------------------------------- ----------------------- -------------------------------
  adrenergic beta-2-receptor (ADRB2)                                                             154                                5q31--q32      3104   9.8      9                   rs1042713                 HR 1.33 (1.06--1.68)      [@pone.0042401-Monraats2]
  advanced glycosylation end product-specific receptor (AGER)                                    177                                  6p21.3       267     UK    6--9                  rs1800624                           ↓               [@pone.0042401-Falcone1]
                                                                                                                                                   297    25.9     6                   rs2070600                          NS                 [@pone.0042401-Shim1]
  angiotensin II receptor, type 1 (AGTR1)                                                        184                                   3q24        272    29.8     6                    rs5186                            NS                [@pone.0042401-Gross1]
                                                                                                                                                   3104   9.8      9                    rs5186                   OR 1.85 (1.28--2.66)      [@pone.0042401-Wijpkema1]
  Butyrylcholinesterase (BCHE)                                                                   590                              3q26.1--q26.2    461    23.2     6                   rs1803274                  OR 5.5 (1.6--21.4)        [@pone.0042401-Oguri1]
  chemokine (C--C motif) ligand 11 (CCL11)                                                      6356                              17q21.1--q21.2   3104   9.8      9                   rs4795895                 HR 0.73 (0.58--0.93)      [@pone.0042401-Monraats2]
  CD14                                                                                           929                                  5q31.1       129     24      6                   rs2569190                  RR 3.8 (1.2--11.6)       [@pone.0042401-Shimada1]
                                                                                                                                                   3104   9.8      9                   rs2569190                 HR 0.74 (0.55--0.99)      [@pone.0042401-Monraats2]
  cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)                                     1027                               12p13.1-p12     433    11.3    12                    rs34330                           NS                [@pone.0042401-Tiroch1]
                                                                                                                                                   2309   8.8      9                  rs36448499                 HR 0.61 (0.40--0.93)      [@pone.0042401-vanTiel1]
  collagen, type III, alpha 1 (Col3A1)                                                          1281                                   2q31        527    9.1      6                   rs1800255                  OR 4.2 (1.4--11.2)        [@pone.0042401-Oguri2]
  colony stimulating factor 2 (CSF2)                                                            1437                                  5q31.1       3104   9.8      9                    rs25882                  HR 0.76 (0.61--0.94)      [@pone.0042401-Monraats2]
  chemokine (C-X3-C motif) receptor 1 (CX3CR1)                                                  1524                                  3p21.3       365    25.5     6                   rs3732379                   OR 2.4 (1.3--4.2)       [@pone.0042401-Niessner1]
  cytochrome b-245, alpha polypeptide (CYBA)                                                    1535                                  16q24        730    35.8     6                    rs4673                     OR 0.5 (0.3--0.8)        [@pone.0042401-Horibe1]
  cytochrome P450, family 2, subfamily C, polypeptide 19 (CYP2C19)                              1557                                  10q24        928    19.1    12                  rs12248560                           ↓                [@pone.0042401-Tiroch2]
  fibrinogen beta chain (FGB)                                                                   2244                                   4q28        527    9.1      6                   rs1800790                   OR 2.7 (1.2--6.2)        [@pone.0042401-Oguri2]
                                                                                                                                                   2257   8.8      9                   rs1800790                          NS               [@pone.0042401-Monraats3]
  coagulation factor V (F5)                                                                     2153                                   1q23        3104   9.8      9                    rs6025                   HR 0.40 (0.19--0.85)        [@pone.0042401-Pons1]
  glutathione peroxidase 1 (GPX1)                                                               2876                                  3p21.3       461    23.2     6                   rs1050450                   OR 2.1 (1.2--3.8)        [@pone.0042401-Oguri1]
  interleukin 10 (IL10)                                                                         3586                                1q31--q32      162    39.5    UK                   rs1800871                 HR 0.39 (0.16--0.94)    [@pone.0042401-MartinezRios1]
                                                                                                                                                   1850   17.6    12                                                      NS                 [@pone.0042401-Koch2]
                                                                                                                                                   3104   9.8      9                   rs3024498                   HR 2.0 (1.4--2.8)       [@pone.0042401-Monraats4]
  interleukin 1 receptor antagonist (IL1RN)                                                     3557                                  2q14.2       183    46.4    12                     VNTR                    HR 5.24 (1.63--16.81)    [@pone.0042401-Marculescu1]
                                                                                                                                                   779    43.9     6                     VNTR                             NS                 [@pone.0042401-Zee1]
                                                                                                                                                   1850   20.3    12                   rs419598                  OR 0.73 (0.58--0.92)      [@pone.0042401-Kastrati1]
  insulin receptor (INSR)                                                                       3643                              19p13.3--p13.2   461    23.2     6                 7,067,365C\>A                 OR 1.9 (1.2--3.1)        [@pone.0042401-Oguri1]
  integrin, beta 2 (ITGB2)                                                                      3689                                 21q22.3       1207   21.2    12                   rs235326                  OR 0.71 (0.55--0.92)        [@pone.0042401-Koch1]
  lipoprotein lipase (LPL)                                                                      4023                                   8p22        3104   9.8      9                     rs328                   OR 0.62 (0.44--0.86)      [@pone.0042401-Monraats5]
  matrix metallopeptidase 12 (MMP12)                                                            4321                                 11q22.3       527    9.1      6                   rs2276109                  OR 3.9 (1.0--12.4)        [@pone.0042401-Oguri2]
  matrix metallopeptidase 9 (MMP9)                                                              4318                              20q11.2--q13.1   461    23.2     6                   rs2664538                   OR 2.0 (1.0--3.9)        [@pone.0042401-Oguri1]
  methylenetetrahydrofolate reductase (NAD(P)H) (MTHFR)                                         4524                                  1p36.3       260    36.9     6                   rs1801133                 OR 3.58 (1.51--8.46)       [@pone.0042401-Chung1]
                                                                                                                                                   800    18.9    12                   rs1801133                          NS                 [@pone.0042401-Koch3]
  nitric oxide synthase 3 (NOS3)                                                                4846                                   7q36        205    29.3     6                   rs2070744                 OR 2.06 (1.08--3.94)       [@pone.0042401-Gomma1]
                                                                                                                                                   901    10.2     9                   rs1799983                 HR 1.67 (1.09--2.54)        [@pone.0042401-Pons2]
                                                                                                                                                   1556   20.8    12                   rs1799983                          NS              [@pone.0042401-Gorchakova1]
  purinergic receptor P2Y, G-protein coupled, 12 (P2RY12)                                       64805                               3q24--q25      2062   8.4      9              Haplotype of 5 SNPs              HR 1.6 (1.2--2.0)        [@pone.0042401-Rudez1]
  serpin peptidase inhibitor, clade E, member 1 (SERPINE1)                                      5054                               7q21.3--q22     1850   20.3    12                   rs1799899                          NS               [@pone.0042401-Bottiger1]
                                                                                                                                                   3104   9.8      9                   rs1799899                 HR 1.26 (1.07--1.49)        [@pone.0042401-Pons1]
  K(lysine) acetyltransferase 2B (KAT2B, PCAF)                                                  8850                                   3p24        3104   9.8      9                   rs2948080                 HR 0.80 (0.67--0.97)        [@pone.0042401-Pons3]
  peroxisome proliferator-activated receptor gamma (PPARG)                                      5468                                   3p25        565    28.7     6                   rs3856806                           ↓              [@pone.0042401-Neugebauer1]
                                                                                                                                                   935    18.3    12                   rs3856806                          NS                 [@pone.0042401-Koch4]
  c-ros oncogene 1, receptor tyrosine kinase (ROS1)                                             6098                                   6q22        461    23.2     6                   rs529038                    HR 1.8 (1.1--2.8)        [@pone.0042401-Oguri1]
  thrombomodulin (THBD)                                                                         7056                                 20p11.2       730    35.8     6                   rs1042579                  OR 2.1 (1.3--3.53)        [@pone.0042401-Horibe1]
  thrombospondin 4 (THBS4)                                                                      7060                                   5q13        628     UK    6--10                 rs1866389                 OR 2.67 (1.04--6.80)     [@pone.0042401-Rittersma1]
  thrombopoietin (THPO)                                                                         7066                                   3q27        527    9.1      6                    rs6141                     OR 2.4 (1.1--5.3)        [@pone.0042401-Oguri2]
  tumor necrosis factor (TNF)                                                                   7124                                  6p21.3       1850   17.6    12                   rs1800629                          NS                 [@pone.0042401-Koch2]
                                                                                                                                                   3104   9.8      9                   rs361525                  HR 0.60 (0.37--0.98)      [@pone.0042401-Monraats1]
  tumor protein p53 (TP53)                                                                      7157                                 17p13.1       132     0      UK                   rs1042522                           ↑                [@pone.0042401-Kojima1]
                                                                                                                                                   433    11.3    12                   rs1042522                          NS                [@pone.0042401-Tiroch1]
                                                                                                                                                   779    43.9     6              Haplotype of 3 SNPs            OR 0.58 (0.40--0.83)        [@pone.0042401-Zee2]
  uncoupling protein 3 (UCP3)                                                                   7352                                 11q13.4       527    9.1      6                   rs1800849                  OR 5.2 (1.9--13.0)        [@pone.0042401-Oguri2]
  vitamin D receptor (VDR)                                                                      7421                                 12q13.11      3104   9.8      9     Haplotype of rs11568820 and rs4516035   HR 0.72 (0.57--0.93)      [@pone.0042401-Monraats6]

The direction of the association between genetic variation and the risk of restenosis, when effect size is not available;↓ protective effect, ↑ deleterious effect. Entrez nr; unique gene ID number used in NCBI database. Abbreviations: UK, unknown; NS, not significant; OR, odds ratio; HR, hazard ratio; RR, relative risk; Ref, reference.

To determine which genes are mainly responsible for this association we subsequently investigated the association of the individual gene based sets. Six of the 36 genes were demonstrated to have an empirical p-value below 0.05 ([Table 3](#pone-0042401-t003){ref-type="table"}). In order of descending p-values the associated genes are; angiotensin II receptor type 1 (AGTR, p = 0.028), glutathione peroxidase 1 (GPX1, p = 0.025), K(lysine) acetyltransferase 2B (KAT2B, also known as PCAF, p = 0.023), matrix metallopeptidase 12 (MMP12, p = 0.019), fibrinogen beta chain (FGB, p = 0.013) and vitamin D receptor (VDR, p = 0.012). Detailed information on the individual SNPs in these genes is depicted in [Table 4](#pone-0042401-t004){ref-type="table"}. The SNP with the lowest individual p-value was rs11574027 in the VDR gene, p = 1.4E-04. In the complete GWAS analysis, which has been published in 2011 [@pone.0042401-Sampietro1], this SNP ranked 116^th^. The strongest association in that analysis was found with a SNP in an intergenic region on chromosome 12, p = 1.0E-06.

Logistic regression models with and without the 11 SNPs described in [Table 4](#pone-0042401-t004){ref-type="table"} demonstrated that together these SNPs explained 9.0% (R Square improved from 0.008 to 0.098) of the occurrence of clinical restenosis in this cohort.

10.1371/journal.pone.0042401.t003

###### Results of individual gene set-based analysis of genes previously associated with restenosis.

![](pone.0042401.t003){#pone-0042401-t003-3}

  Gene        Chr   Start (bp)     End (bp)     Size (kb)   SNPs   Sign. SNPs   Indep. SNPs    P-value
  ---------- ----- ------------- ------------- ----------- ------ ------------ ------------- -----------
  ADRB2        5    148 186 349   148 188 381     2.03       32        8             2          0.088
  AGER         6    32 256 724    32 260 001      3.28       37        1             1          0.228
  AGTR1        3    149 898 348   149 943 480     45.13     100        5             1        **0.028**
  BCHE         3    166 973 387   167 037 944     64.56     101        8             2          0.314
  CCL11       17    29 636 800    29 639 312      2.51       18        0             0          1.000
  CD14         5    139 991 501   139 993 439     1.94       22        4             2          1.000
  CDKN1B      12    12 761 576    12 766 569      4.99       13        0             0          1.000
  Col3A1       2    189 547 344   189 585 717     38.37      97        2             2          0.649
  CSF2         5    131 437 384   131 439 757     2.37       28        0             0          0.965
  CX3CR1       3    39 279 990    39 596 531     316.54     384        3             1          0.358
  CYBA        16    87 237 199    87 244 958      7.76       14        1             1          0.182
  CYP2C19     10    96 512 453    96 602 660      90.21      43        1             1          1.000
  FGB          4    155 703 596   155 711 686     8.09       25        2             1        **0.013**
  F5           1    167 747 816   167 822 393     74.58     200        1             1          1.000
  GPX1         3    49 369 615    49 370 795      1.18       8         1             1        **0.024**
  IL10         1    205 007 571   205 012 462     4.89       30        5             1        **0.053**
  IL1RN        2    113 601 609   113 608 063     6.45       62        0             0          0.991
  INSR        19     7 063 266     7 245 011     181.75     172        20            5          0.263
  ITGB2       21    45 130 299    45 165 303      35.00      57        6             4          0.663
  LPL          8    19 841 058    19 869 049      27.99      75        14            5          1.000
  MMP12       11    102 238 675   102 250 922     12.25      36        3             3        **0.019**
  MMP9        20    44 070 954    44 078 606      7.65       23        10            3          0.067
  MTHFR        1    11 768 374    11 788 702      20.33      61        1             1          1.000
  NOS3         7    150 319 080   150 342 608     23.53      20        0             0          0.987
  P2RY12       3    152 538 066   152 585 234     47.17     121        0             0          1.000
  SERPINE1     7    100 556 303   100 558 421     2.12       27        0             0          0.863
  KAT2B        3    20 056 528    20 170 898     114.37     144        19            4        **0.023**
  PPARG        3    12 304 349    12 450 854     146.51     144        14            5          1.000
  ROS1         6    117 716 223   117 853 711    137.49     206        1             1          0.631
  THBD        20    22 974 271    22 978 301      4.03       22        0             0          1.000
  THBS4        5    79 366 747    79 414 861      48.11      61        3             2          0.292
  THPO         3    185 572 467   185 578 626     6.16       16        1             1          0.165
  TNF          6    31 651 329    31 654 089      2.76       41        2             2          0.370
  TP53        17     7 512 445     7 531 642      19.20      17        1             1          0.120
  UCP3        11    73 388 958    73 397 778      8.82       34        1             1          0.183
  VDR         12    46 521 589    46 585 081      63.49      93        2             2        **0.012**

Chromosome and genomic region based on HapMap Rel 28 Phase II+III. P-value based on permutation (10,000). Abbreviations: SNPs, number of SNPs in genomic region including 10 kb window; Sign.SNPs, number of SNPs with p\<0.05; Indep.SNPs, number of significant and independent SNPs, considering threshold of R^2^\<0.1.

10.1371/journal.pone.0042401.t004

###### Significantly associated SNPs of the 6 top genes.
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                                                                  MAF                             Imputation  
  ------- ------------ ---- ----------- ------------------ ----- ------ ------- ------ --------- ------------ -------
  AGTR1      rs5182     3    149942085   Exon, synonymous   T/C   0.43   0.50    0.75   0.0040    Genotyped     --
  FGB      rs1044291    4    155712802        3′UTR         T/C   0.38   0.30    1.40   0.0028     Imputed     0.970
  GPX1     rs8179164    3    49372288        Promoter       A/T   0.02   0.04    0.42   0.0077     Imputed     0.993
  MMP12    rs12808148   11   102238373      Downstream      C/T   0.16   0.09    1.82   0.00021    Imputed     0.953
           rs17099726   11   102257062       Promoter       G/T   0.03   0.06    0.54    0.032     Imputed     0.957
  KAT2B    rs6776870    3    20126544         Intron        G/C   0.14   0.21    0.62   0.00064    Imputed     0.999
           rs2929404    3    20069570         Intron        T/C   0.21   0.15    1.49   0.0026     Imputed     0.981
           rs17796904   3    20096353         Intron        T/C   0.16   0.12    1.43    0.012    Genotyped     --
           rs4858767    3    20141941         Intron        G/C   0.29   0.34    0.79    0.037     Imputed     0.994
  VDR      rs11574027   12   46573640         Intron        T/G   0.03   0.007   4.19   0.00014   Genotyped     --
           rs11574077   12   46539194         Intron        G/A   0.07   0.04    1.60    0.029    Genotyped     --

SNP, single nucleotide polymorphism; Chr, chromosome; bp, base pair; MAF, minor allele frequency in control group; OR, odds ratio. The imputation quality indicates the average posterior probability for the most likely genotype generated by MACH, ranging from 0--1.

As a final analysis we removed the 6 significantly associated genes from the complete set. Subsequent analysis of the subset of the other 30 genes did not demonstrate a remaining joined effect, p = 0.65 after 10,000 permutations.

Discussion {#s4}
==========

With this study we aimed at clarifying the ambiguities regarding genetic predisposition for developing restenosis after PCI. We show that the joined effect of the complete spectrum of candidate genes, so far proposed to be involved in the restenotic process, results in a significant association with restenosis. This association is determined by six individual genes. Analyzing a subset containing the 30 genes not associated with the endpoint on an individual basis, did not show a remaining joined effect, making the involvement of genetic variation in these genes on restenosis development more unlikely.

The six associated genes span a wide range of different functions underlining the complexity of the disease. When examining the biological pathways with involvement of these genes, only the VDR and KAT2B genes share a common pathway. The genes are both involved in the Vitamin D receptor pathway described by BioCarta.[@pone.0042401-Biocarta1] This pathway mainly involves the transcriptional regulating capacities of this receptor and is involved in controlling cellular growth, differentiation and apoptosis. Since these processes are all thought to be important contributors to the restenotic process, this indeed is a plausible pathway to be involved in restenosis development.[@pone.0042401-Jukema1].

The rationale of set-based analysis is to overcome the marginally weak effect of single SNPs by analyzing a set of SNPs, since these SNPs could jointly have strong genetic effects. Most studies utilizing the candidate gene approach analyzed only one or at most a few SNPs within the gene of interest. The likelihood that exactly those SNPs are the causal or associated SNPs is of course small. A broader approach, like this set-based analysis, is therefore more likely to detect an associated gene by combining multiple SNPs with a possible marginal individual effect.[@pone.0042401-Fridley1], [@pone.0042401-Torkamani1] For the current study we used the PLINK software [@pone.0042401-Purcell1], although multiple statistical programs are available for this type of analysis. Gui et al. compared 7 tests analyzing the WTCCC Crohn's Disease dataset.[@pone.0042401-Gui1] One of their overall conclusions was that the set-based test in PLINK was the most powerful algorithm. Another study, applying PLINK set-based test, Global test, GRASS and SNP ratio test, for the analysis of three pathways regarding human longevity observed similar results with the different tests.[@pone.0042401-Deelen1].

For the current study we analyzed the data using a threshold of linkage disequilibrium defined by R^2^≥0.1. The standard setting in PLINK is a R^2^ of 0.5. In our opinion this threshold is too high for the intended analysis for this study. A higher threshold will include more SNPs in higher LD, which would be unfavorable, since we were interested in independent loci contributing to the risk of restenosis. By decreasing this threshold, only SNPs were selected that had a R^2^ below 0.1, and thus independent of each other.

Although hypertension and multivessel disease were more frequent in cases compared to controls we decided not to correct for these variables. In the complete GENDER population these variables were not independent predictors for restenosis development [@pone.0042401-Agema1], so the differences in the current subpopulation likely resulted by chance during the selection process. Also, other studies provide no convincing data that hypertension is related to restenosis [@pone.0042401-Jukema1]. It is therefore unlikely that previous associations of some of the current candidates genes (VDR, FGB, AGTR1 and GPX1) with hypertension[@pone.0042401-Swapna1]--[@pone.0042401-Mansego1], have influenced our results, although this cannot be completely excluded.

A limitation of the current study could be that we analyzed imputed genotypic data, which introduces some amount of uncertainty. However, since we were interested in the combined effect of SNPs, an extensive genomic coverage was paramount for this analysis. Only analyzing the genotyped GWAS data would have resulted in the coverage of some of the smaller genes by only 1 or 2 SNPs. Therefore we decided that the more extensive genomic coverage of the imputed dataset outweighed the small introduction of possible error. A second limitation is that the analyses were only performed in the GENDER population. Availability of other populations with thorough genetic data on restenosis is however very limited. To our knowledge, the GWAS on restenosis in the GENDER population is the first, and only, examining this endpoint on a genome wide scale. Finally, the conclusions of this study are only based on genetic analyses. Functional studies should be performed to elucidate the biological consequences of these findings.

In conclusion, with these results we demonstrate that the efforts in unraveling the genetic factors influencing the risk of restenosis of the last years has resulted in a set of genes that joint together is indeed likely to be associated with restenosis, despite the overt inconsistencies of the individual studies. Confirmation of the association of these genes with the occurrence of restenosis after PCI helps our understanding of the genetic etiology of the disease. Future additional research strategies, like biological pathway analysis of GWAS data or even (exome) sequencing, might help us find the missing heritability of restenosis after PCI and increase our knowledge of the biological mechanistic background of restenosis development. This knowledge could subsequently result in identification of new treatment targets or development of novel preventive measure or risk stratification models.
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